Careers
|
Partnerships
|
Contact
|
Login
Response Biomedical logo

Procalcitonina como predictor de sepsis precoz en cirugía cardiovascular.

Perspectivas para mejorar la atención y el diagnóstico del paciente
46 min
Explora el valor clínico de la procalcitonina (PCT) como biomarcador temprano de sepsis en pacientes sometidos a cirugía cardiovascular con circulación extracorpórea. Conoce cómo los niveles de PCT a las 24 y 72 horas postoperatorias pueden apoyar un diagnóstico oportuno y mejorar los resultados en pacientes de alto riesgo.
Objetivos clave de aprendizaje:
  • Procalcitonina en la cirugía cardiovascular: Comprende la importancia de la procalcitonina como biomarcador sérico en pacientes sometidos a cirugía cardíaca con CEC y cómo ayuda a diferenciar entre inflamación postoperatoria normal y sepsis temprana.
  • Implementación clínica en el cuidado postoperatorio: Aprende cómo las pruebas de PCT en el punto de atención (POCT) se integran en los protocolos de UCI postquirúrgica para monitorear a pacientes de alto riesgo y optimizar su recuperación.
  • Correlación con resultados de sepsis: Revisa hallazgos que relacionan niveles elevados de PCT con un mayor riesgo de sepsis postoperatoria, estancias hospitalarias prolongadas y necesidad de transfusiones sanguíneas.
  • Perfiles microbianos y patrones de Resistencia: Identifica los patógenos más comunes, como Escherichia coli, encontrados en casos de sepsis tras cirugía cardíaca, y analiza las implicaciones para el control de infecciones y estrategias antibióticas empíricas.
Este webinar busca profundizar en el papel de la procalcitonina como biomarcador clave para el diagnóstico y manejo temprano de la sepsis en pacientes sometidos a cirugía cardiovascular.

Contact Our Specialists

24 hour Technical Support available to all RAMP Customers

Faster

Improves turnaround time
for faster triage

Accurate

Provides high quality results
with built in QC

Reliable

Enables clinicians to make
informed decisions
©2025 Response Biomedical. All Rights reserved

You will be able to participate in this research study if you are:

  • 18 years of age or older.
  • In good health.
  • Willing to voluntarily agree to sign the consent form.

You will not be able to participate in this research study if:

  • You are considered/consider yourself to be a vulnerable subject (e.g., nursing home residents, institutionalized persons, pregnant and nursing women, children under the age of 19, prisoners, or persons with decisional incapacity).
  • You are currently diagnosed with, or have a history of, underlying major medical conditions (for example: heart disease, hypertension, stroke, renal disease, diabetes and bleeding disorders).
  • You are actively in hemodialysis treatment.
  • You have been told that you have HIV, chronic active hepatitis B, or chronic, active hepatitis C.
  • You have been hospitalized (for more than 24 hours) in the past three months.
  • You are actively receiving treatment or monitoring for certain cancers (excluding non-melanoma skin cancers and localized prostate cancer not requiring systemic therapy).
  • You are already enrolled in this study.
  • You are unable and/or unwilling to provide informed consent.
If you are interested in participating in this study, you can schedule a time to virtually meet with the clinical team at Response Biomedical. During your online meeting, Response Biomedical will send you a self-assessment questionnaire via DocuSign to determine eligibility. If you are eligbile to participate, a team member will explain the study in detail, review the consent form with you, and send the consent form to you for electronic signature. Once you have signed the consent form, the study staff will arrange an appointment for you at a nearby LifeLabs location.

To participate in this study at a LifeLabs location, you will need to be able to print a paper copy of the requisition to take with you to your appointment. If you do not have access to a printer but would still like to participate, you can book an appointment at the Response Biomedical location or attend a community collection event.
At your LifeLabs appointment, a trained LifeLabs professional will collect two (2) 4 mL tubes of whole blood—approximately two teaspoons.
After collection, your blood sample will be sent to Response Biomedical, where a trained operator will use it to perform the RAMP® hs-TnI test.

Book A Demo

"*" indicates required fields

Name*

Meet Us at the Event

"*" indicates required fields

Name*

Technical Support

"*" indicates required fields

Name*

Get A Quote

"*" indicates required fields

Name*

Partnership

"*" indicates required fields

Name*

You will be able to participate in this research study if you are:

  • 18 years of age or older.
  • In good health.
  • Willing to voluntarily agree to sign the consent form.

You will not be able to participate in this research study if:

  • You are considered/consider yourself to be a vulnerable subject (e.g., nursing home residents, institutionalized persons, pregnant and nursing women, children under the age of 19, prisoners, or persons with decisional incapacity).
  • You are currently diagnosed with, or have a history of, underlying major medical conditions (for example: heart disease, hypertension, stroke, renal disease, diabetes and bleeding disorders).
  • You are actively in hemodialysis treatment.
  • You have been told that you have HIV, chronic active hepatitis B, or chronic, active hepatitis C.
  • You have been hospitalized (for more than 24 hours) in the past three months.
  • You are actively receiving treatment or monitoring for certain cancers (excluding non-melanoma skin cancers and localized prostate cancer not requiring systemic therapy).
  • You are already enrolled in this study.
  • You are unable and/or unwilling to provide informed consent.
If you agree to take part in this study, study staff will discuss a consent form with you. After you sign the consent form, a phlebotomist will collect a blood sample from you. This will include two (2) 4mL tubes worth of whole blood, which is slightly less than 2 teaspoons. Once the blood has been collected, a trained operator will use your blood sample to perform the RAMP® hs-TnI test. The entire visit should last around 30 minutes.Â